---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-24-000014"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:35:46.267439+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NovoCure Q1 net revenue up 13% to $138.5M; METIS trial meets endpoint, FDA decision on lung cancer PMA expected H2 2024

## Summary
- Net revenue $138.5M (+13% YoY); net loss $38.8M ($0.36 loss per share); adjusted EBITDA -$4.6M.
- Active patients 3,845; prescriptions received 1,643 (+10% YoY).
- METIS Phase 3 met primary endpoint (brain metastases from NSCLC); will be presented at ASCO.
- LUNAR PMA for Optune Lua in NSCLC: Day 100 FDA meeting productive, decision expected H2 2024.
- Entered $400M senior secured credit facility with Pharmakon Advisors (non-dilutive).

## SEC filing metadata
- accession: 0001645113-24-000014
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000014/0001645113-24-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000014/nvcr-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-24-000014
- JSON: https://secwatch.observer/filing/0001645113-24-000014.json
- Plain text: https://secwatch.observer/filing/0001645113-24-000014.txt

## Key facts
- Earnings Releases
  NovoCure Ltd reported quarter ended March 31, 2024 results: revenue $138.5 million, net income $38.8 million, EPS $0.36.
  - Period: quarter ended March 31, 2024
  - Revenue: $138.5 million
  - Net income: $38.8 million
  - EPS: $0.36
  - Result: reported results
  source text: Total net revenues for the quarter were $138.5 million, an increase of 13% compared to the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000014/0001645113-24-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.